Left: Human Skeletal Muscle Cells, HSkMC.
Right: FusedHSkMC (fetal) immunolabeled for desmin (green). Nuclei are visualized with PI (red).
Human Skeletal Muscle Cells (HSkMC) are isolated from the skeletal muscle of limbs from adult or fetal donors. Human Skeletal Muscle Cells can undergo differentiation to exhibit actin and myosin myofilaments. HSkMC from Cell Applications, Inc. provide a useful model system to study many aspects of muscular function and disease.
Skeletal Muscle Cells play an instrumental role in the glucose metabolism and diabetes, therefore select HSkMC lots undergo an additional set of characterization at Cell Applications, Inc. to demonstrate AMPK signaling and responsiveness to insulin stimulation. For more information on Pre-screened Skeletal Muscle Cells click here.
Characterization: Positive for sarcomere myosin.
HSkMC from Cell Applications, Inc. have been used to:
- serve as a differentiated control in a study of developmental regulator genes in hESC (Lee, 2006);
- characterize statin-induced gene expression changes and demonstrate cytotoxic effect of statins in skeletal muscle cells (Morikawa, 2005; Yamazaki, 2006; Xu, 2009);
- identify molecular mechanisms of mitochondrial myopathy and sideroblastic anemia resulting from a missense mutation in the PUS1 gene (Patton, 2005); investigate chemokine-like factor expression in the idiopathic inflammatory myopathies (Chowdhury, 2008); and demonstrate that fasting activates AceCS2 gene expression by inducing KLF15 transcription factor (Yamamoto, 2004);
- characterize human FGFR3-positive sarcoma-initiating stem cells (Hirotsu, 2009), and identify trans-Golgi network proteins and Notch and Hedgehog pathways as putative targets for rhabdomyosarcoma therapy (Kawabata, 2011; Kinigou, 2011; Nagao, 2012);
- show that riluzole muscle relaxant effects are mediated by inhibition of INa and stimulation of BKC-channel activity (Wang, 2008); and develop nitric esters that combine the pharmacological functions of NO and muscle relaxation properties for treatment of muscular diseases (Wang, 2013);
- develop biodegradable polymer-based transgene delivery vectors for muscular dystrophy treatment (Wang, 2012) and design optimal coating for orthopedic metallic implants (Perla, 2005, 2006).
Normal human limb skeletal muscle. Each lot is tested negative for HIV, Hepatitis B, Hepatitis C, mycoplasma, bacteria, and fungi.
2nd passage, >500,000 cells in Basal Medium containing 10% FBS & 10% DMSO.
Ampoule of cryopreserved (150-05f), 500 ml of HSkMC Growth Medium (151-500), and a Subculture Reagent Kit (090K).
Shipped in Transfer Medium at 3rd passage in either flasks or multiwell dishes.
Can be cultured at least 15 doublings
Iizuka, K., T. Machida, and M. Hirafuji. 2014. Extracellular MCT4 Is a Possible Indicator for Skeletal Muscle MHC Fiber Type Change. Ann Clin Lab Sci, 44:272-276.
Wang, G., and Q. Lu. 2013. A nitrate ester of sedative alkyl alcohol improves muscle function and structure in a murine model of Duchenne muscular dystrophy. Molecular pharmaceutics. 10:3862-3870.
Nagao, H., T. Setoguchi, S. Kitamoto, Y. Ishidou, S. Nagano, M. Yokouchi, M. Abematsu, N. Kawabata, S. Maeda, S. Yonezawa, and S. Komiya. 2012. RBPJ Is a Novel Target for Rhabdomyosarcoma Therapy. PloS one. 7:e39268.
Wang, M., J.D. Tucker, P. Lu, B. Wu, C. Cloer, and Q. Lu. 2012. Tris[2-(acryloyloxy)ethyl]isocyanurate Cross-Linked Low-Molecular-Weight Polyethylenimine as Gene Delivery Carriers in Cell Culture and Dystrophic mdx Mice. Bioconjugate chemistry. 23:837-845.
Kawabata, N., K. Ijiri, Y. Ishidou, T. Yamamoto, H. Nagao, S. Nagano, S. Maeda, S. Komiya, and T. Setoguchi. 2011. Pharmacological inhibition of the Hedgehog pathway prevents human rhabdomyosarcoma cell growth. International journal of oncology. 39:899.
Kunigou, O., H. Nagao, N. Kawabata, Y. Ishidou, S. Nagano, S. Maeda, S. Komiya, and T. Setoguchi. 2011. Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncology reports. 26:1337-1342.
Thuangtong, R., J.J. Bentow, K. Knopp, N.A. Mahmood, N.E. David, and M.S. Kolodney. 2010. Tissue‐Selective Effects of Injected Deoxycholate. Dermatologic Surgery. 36:899-908.
Gupta, A., C. Lobocki, S. Singh, M. Robertson, O.A. Akadiri, G. Malhotra, and I.T. Jackson. 2009. Actions and Comparative Efficacy of Phosphatidylcholine Formulation and Isolated Sodium Deoxycholate for Different Cell Types. Aesth Plast Surg. 33:346-352.
Hirotsu, M., T. Setoguchi, Y. Matsunoshita, H. Sasaki, H. Nagao, H. Gao, K. Sugimura, and S. Komiya. 2009. Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer. 101:2030-2037.
Xu, J.J., and J.Y. Li. 2009. Focus on the Fundamentals: Toward Better Therapeutic Index Prediction. Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools. 4:1.
Xu, J.J., and J.Y. Li. 2009. Focus on the Fundamentals: Toward Better Therapeutic Index Prediction. Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools. 1:3-28.